Chembio Diagnostics Inc. (CEMI) soared 159.22% for July 21

Equities Staff  |

Chembio Diagnostics Inc. (NASDAQ: CEMI) shares soared 159.22%, or $3.28 per share, to close Wednesday at $5.34. After opening the day at $4.02, shares of Chembio Diagnostics fluctuated between $6.95 and $3.83. 396,463,232 shares traded hands an increase from their 30 day average of 524,841. Wednesday's activity brought Chembio Diagnostics’s market cap to $108,105,918.

About Chembio Diagnostics Inc.

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Visit Chembio Diagnostics Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Chembio Diagnostics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Chembio Diagnostics Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content